We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.30 | -4.62% | 6.20 | 5.52 | 6.48 | 6.00 | 6.00 | 6.00 | 197,722 | 16:35:05 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.68 | 12.08M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/3/2020 14:42 | Best, why the ethical dilemma.None of us wish this crisis to persist. The sooner we are done with it, the betterI once refused to get involved (on ethical grounds) with a company when the shares were 50p, but eventually became a shareholder when they were 15 quidI guess it's how u define 'ethical' | yet another final | |
20/3/2020 14:37 | Excellent day for SNG ....the trials and the share price! | hazl | |
20/3/2020 14:36 | Agree, safe and tested to a degree | yet another final | |
20/3/2020 14:32 | Dont overlook the fact SNG001 is not for COVID 19 alone. It is for Asthma COPD and influenza viruses. P2 studies have pointed to success which had opened the door for the COVID 19 trial | tidy 2 | |
20/3/2020 14:29 | Shake time...they want your shares! Going to fly into close. | likya123 | |
20/3/2020 14:27 | Have reframed from posting on this stock apart from a small snippet yesterday from an ethical point of view it does not sit well with me .Im keeping my fingers crossed that for the many in ITC that it can moderate the Most severe of symptoms. | best1467 | |
20/3/2020 14:25 | Careful what u say about NCYT cos u will incur their wrath, and their drivel about how to fight this pandemic....Yes PAN....everywhere, so now the strategy is to 1) prevent infection (vaccines which are months away) 2) manage infection with the aim of reducing severity of infections and its consequences. So it's a case of flattening the pyramid (spectrum of disease), whereby without proper therapies, say 10% will be very severe and of that group 25% die. If SNG now reduces the severe group to 8% (rather than 10) then you can potentially save one life for every ten severely ill patients treated- my calculations are not exact but I'm trying to demonstrate the benefit, so don't reply and criticise my NNT (for those who know what that means)Having mentioned NCYT, I anticipate this will mimic its share price performance in the early days, perhaps reaching intraday highs next Monday or Tuesday....you can refer to my posts in February when I predicted the behaviourPromisingGL | yet another final | |
20/3/2020 14:17 | Don't do it too early I expect more ncyt guys to start joining here | jayminpatel1 | |
20/3/2020 14:16 | Also posted on the other thread. So if I'm reading this correctly the lungs are protected by this inhaled interferon beta, hence if you get this virius and don't take this your lungs are permanently damaged. Furthermore, viruses, such as severe acute respiratory syndrome (SARS-CoV-2) and MERS-CoV, have evolved mechanisms that suppress endogenous IFN-beta production, thereby helping the virus evade the innate immune response. Research conducted in Hong Kong revealed that patients who recovered from the coronavirus had sustained lung damage, and therefore it is possible that patients may not fully recover their lung function following the infection. Synairgen’s SNG001, a formulation of IFN-beta-1a for direct delivery to the lungs via nebulization, will, therefore, prevent cell damage in a similar fashion to that of MS patients. | 2nell | |
20/3/2020 14:10 | Can see this flying past 50p before close | jayminpatel1 | |
20/3/2020 14:06 | Inhaled interferon-beta launches into the fight against the Covid-19 pandemichTTps://www. | tidy 2 | |
20/3/2020 14:06 | But not every 5 minutes | nobbygnome | |
20/3/2020 14:03 | You keep repeating posts too about the fact you can’t moderate :). I’m only trying to help newcomers and shareholders realise how significant this is at. A time of crisis | saw89 | |
20/3/2020 14:02 | The world is desperate for solutions. All bets off if it goes well with the 100 NHS patient trials. | saw89 | |
20/3/2020 13:59 | Easily 3 or 4 bag in anticipation of positive feedback in the next week or 2. Given this is being used on patients in critical condition, we will know quickly if it works well and has a positive impact. | saw89 | |
20/3/2020 13:56 | Inhaled interferon-beta launches into the fight against the Covid-19 pandemicToday 13:56 And another big pharma site, it's everywhere! | likya123 | |
20/3/2020 13:52 | Synairgen's other current activities with COVID-19Since the outbreak of COVID-19, Synairgen has been approached by, and is in discussion with, a number of other medical, scientific, and Governmental bodies (both in the UK, US and internationally) seeking to investigate novel therapeutics in this area. | tidy 2 | |
20/3/2020 13:39 | I see what you mean but it's simpler to just talk about the total number of shares traded. Plus the free float is really quite low....that is why the price is going up so much. There are very few free shares to buy especially if the current holders don't trade out.... | nobbygnome | |
20/3/2020 13:35 | Nobby - need to divide by 2! | toffeeman | |
20/3/2020 13:34 | Thanks, let's hope we get some positive results! | 3fiona | |
20/3/2020 13:33 | Current Mcap ~£40m | saw89 | |
20/3/2020 13:33 | NCYT hit £150m Mcap on hype for some £4 test kits. This is a TREATMENT being trialled by the NHS as a life saving measure on 100 critical condition patients in several NHS trusts. | saw89 | |
20/3/2020 13:30 | No-one can be sure of anything. However, IMHO the price will be considerably higher than it is now close to the results. | nobbygnome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions